Biorce has raised $58.0M in total across 2 funding rounds.
Biorce's investors include DST Global, Albert Nieto, Arthur Mensch, MSM, Nikolay Storonsky, Norrsken VC, Paulo Rosado, YZR Capital, EQT Ventures.
Biorce is a Barcelona-based medtech startup founded in 2024 that develops artificial intelligence solutions to accelerate drug development. Its flagship product, the AI-native clinical platform Jarvis, streamlines clinical trial design, patient recruitment, protocol feasibility, and regulatory planning. By leveraging insights from over 530,000 clinical studies, Jarvis helps clinical teams make smarter decisions early, reducing costly delays and errors. Biorce primarily serves pharmaceutical companies and clinical research organizations, addressing inefficiencies that slow down bringing new treatments to market. The platform aims to reduce trial timelines by up to 50%, enabling faster patient access to life-saving therapies[1][2][3][4][5].
Biorce was founded in 2024 by Pedro Coelho, whose personal experience with his father’s cancer treatment inspired the company’s mission. Witnessing the life-extending impact of clinical trials firsthand, Coelho sought to tackle the root causes of delays and inefficiencies in clinical research, which often stem from poorly designed protocols and operational errors. The company quickly gained traction by developing Jarvis, an AI assistant trained on extensive clinical trial data, and secured €3.5 million in seed funding led by impact VC Norrsken in late 2024. This investment underscored confidence in Biorce’s potential to revolutionize clinical trials and improve patient outcomes[1][4][5].
Biorce rides the rising trend of applying artificial intelligence to healthcare, specifically clinical research, where inefficiencies have long hindered drug development. The timing is critical as pharmaceutical companies face increasing pressure to reduce costs and accelerate time-to-market for new treatments. Regulatory complexity and the sheer volume of clinical data create a strong market need for AI-driven solutions that can optimize trial design and execution. By simplifying and automating these processes, Biorce not only improves operational efficiency but also enhances patient outcomes by speeding access to innovative therapies. This positions Biorce as a key player in the digital transformation of clinical trials, influencing the broader ecosystem of medtech, pharma, and health AI[1][2][4][6].
Looking ahead, Biorce is poised to expand its platform capabilities and geographic footprint, potentially integrating more real-world data and advanced AI models to further refine clinical trial processes. As regulatory bodies increasingly embrace digital tools, Biorce’s AI-native approach could become a new standard in trial design and management. The company’s influence may grow beyond drug development into broader medical research and healthcare delivery, driving systemic improvements in how treatments are tested and brought to patients. Continued investment and partnerships will be crucial to scaling impact, but Biorce’s foundation in deep clinical expertise and cutting-edge AI positions it well for sustained growth and innovation in the medtech landscape[3][4][5].
Biorce has raised $58.0M across 2 funding rounds. Most recently, it raised $52.0M Series A in February 2026.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 2, 2026 | $52.0M Series A | DST Global | Albert Nieto, Arthur Mensch, MSM, Nikolay Storonsky, Norrsken VC, Paulo Rosado, YZR Capital |
| Jul 1, 2025 | $6.0M Seed | EQT Ventures, Norrsken VC |
